1 / 2

Mean change from baseline in glycated hemoglobin over time after alogliptin vs. placebo

Mean change from baseline in glycated hemoglobin over time after alogliptin vs. placebo. Mean (±SD) glycated hemoglobin at baseline Placebo, 8.03±1.11% Alogliptin , 8.03±1.09%. Placebo (N=2679). Mean Change in Glycated Hemoglobin (%). Alogliptin (N=2701). White e t al. NEJM 2013.

hertz
Télécharger la présentation

Mean change from baseline in glycated hemoglobin over time after alogliptin vs. placebo

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Meanchangefrom baseline in glycatedhemoglobin over time afteralogliptinvs.placebo Mean (±SD) glycated hemoglobin at baseline Placebo, 8.03±1.11% Alogliptin, 8.03±1.09% Placebo (N=2679) Mean Change in Glycated Hemoglobin (%) Alogliptin (N=2701) White et al. NEJM 2013

  2. Time to firstoccurrence of primaryendpointafteralogliptinvs. placebo Hazard ratio, 0.96 (upper boundary of the one-sided repeated CI, 1.16) 24 18 Cumulative Incidence of Primary End-Point Events (%) Placebo 12 Alogliptin 6 6 12 18 24 30 Months White et al. NEJM 2013

More Related